ACR

Live Varicella Vaccine Is Safe and Effective in Patients Taking TNF Inhibitors

November 22, 2019

The safety of live virus vaccines in patients receiving biologic therapies was confirmed in a study of 617 patients recently presented at the American College of Rheumatology annual meeting this month.

Senior Rheumatoid Arthritis Patients May Be Missing Out on Treatments

November 22, 2019

Even though senior patients with rheumatoid arthritis receive biologic therapies less often than patients who develop the condition early in life, a Japanese study presented this month at the ACR annual meeting, shows that patients 60 years and older can benefit from therapy just as much as younger patients.

Study Shows Promise in Immunotherapy for Rheumatoid Arthritis

November 22, 2019

Researchers are exploring the possibility of using immune checkpoint inhibitors in rheumatoid arthritis patients. A small study presented at the American College of Rheumatology (ACR) annual meeting earlier this month shows that rheumatoid arthritis (RA) patients who were treated with immunotherapy, responded just as well as a comparable patient population with only 12 of 22 patients experiencing flares.

Trial Shows Switch from Etanercept Biologic to Biosimilar Maintains Clinical Outcomes

November 20, 2019

A new study shows that the clinical status of patients who have either rheumatoid arthritis or axial spondyloarthritis, can be successfully maintained when switching from the biologic originator etanercept to a biosimilar called SB4.

Methotrexate Controls Joint Damage in Hand Osteoarthritis, Small Study Shows

November 18, 2019

The first-ever study designed to assess the effectiveness of methotrexate on hand osteoarthritis finds that while the treatment did not demonstrate superior efficacy over placebo on pain or function, it did significantly reduce the progression of joint damage.

Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis

November 18, 2019

Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.

New Etiology of Rheumatoid Arthritis Identified in the Gut Microbiome

November 18, 2019

Scientists now have a better understanding of the relationship between the gut microbiome and rheumatoid arthritis.

One Step Closer for Macrophage Activation Syndrome Testing in Juvenile Arthritis

November 18, 2019

Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.

ACR Annual Meeting Roundup: Higher death rates in lupus

November 14, 2019

In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.

Exposure to Industrial Air Pollutants Linked to Rheumatoid Arthritis Biomarker

November 13, 2019

ACR Annual Meeting:  Exposure to industrial emissions of fine particles matter and sulfur dioxide are associated with the presence of anti-citrullinated protein antibodies, a characteristic biomarker for rheumatoid arthritis, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.

x